Anil Kumar Prajapati

Mr. Anil Kumar Prajapati


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2024 in IP International Journal of Comprehensive and Advanced Pharmacology
Verified
Journal Article
Open access
PDF file
ANAnil
Anil
KUKumar
Kumar
APAnil Kumar Prajapati
Anil Kumar Prajapati
Chronic heart failure occurs when the heart's capacity to effectively pump blood becomes disrupted, resulting in insufficient oxygen and nutrient delivery to the body's tissues. Cardiac fibrosis, a common pathophysiological process in cardiovascular diseases like myocardial infarction and hypertension, results from the increased accumulation of extracellular matrix (ECM) by activated cardiac fibroblasts (CFs). The stimulation of fibroblasts is prompted by pro-inflammatory signaling molecules and neuroendocrine activators and ventricular wall stretch, which is observed in conditions such as pressure overload or injury following a myocardial infarction. These activated fibroblasts transform into myofibroblasts, which play a crucial role in ECM secretion and cardiac fibrosis. TGF-βs are multifunctional cytokines involved in regulating various cell processes, including inflammation, ECM deposition, cell proliferation, differentiation, and growth. TGF-β stimulation promotes myofibroblast differentiation and increases ECM protein synthesis. It also activates pro-fibrotic genes by increasing Smad2/3 while reducing inhibitory Smad 6/7 in myofibroblasts. Smad 2/3 activation has been observed in fibroblasts infiltrating remodeling hearts after injury. TGF-β further contributes to collagens I, III, and VI deposition, enhancing matrix protein expression in the heart. Despite some attempts to target TGF-β3 signaling at the ALK1-5 receptor activity level, the success has been limited. However, additional research is needed to explore and develop therapies focused on the TGF-β signaling pathway to address cardiac dysfunction and heart failure.

15 June 2024 in Journal of Preventive Medicine and Holistic Health
Verified
Journal Article
Open access
PDF file
APAnil Kumar Prajapati
Anil Kumar Prajapati
Herbal drugs, also known as phytochemicals or botanical medicines, are a cornerstone of traditional healthcare, with the World Health Organization (WHO) noting their reliance by approximately 80% of the global population. Despite their historical and widespread use, the assumption of their inherent safety due to natural origins is misleading. The significance of toxicological profiling and standardization to ensure the safe use of herbal medicines. Challenges such as species substitution and adulteration highlight the urgent need for regulatory oversight and stringent quality control. Various bioactive compounds in herbs can pose severe health risks, necessitating comprehensive toxicity evaluations using OECD guidelines. Regulatory frameworks across different regions, including the FDA in the United States, EMA in Europe, and the Ministry of AYUSH in India, are pivotal in maintaining the safety and efficacy of these products. Strategies to mitigate herbal drug toxicity include standardization of manufacturing processes, adherence to Good Manufacturing Practices (GMP), robust regulatory compliance, extensive research on toxicity profiles, education of stakeholders, and vigilant monitoring of adverse events. These measures are essential to fostering the responsible use of herbal medicines and safeguarding public health.

15 June 2024 in IP International Journal of Comprehensive and Advanced Pharmacology
Verified
Journal Article
Open access
PDF file
APAnil Kumar Prajapati
Anil Kumar Prajapati
AJAshish Kumar Jha
Ashish Kumar Jha
DSDevang Sheth
Devang Sheth
Diabetes mellitus (DM) represents a multifaceted metabolic disorder characterized by hyperglycemia and dysregulated metabolism, stemming from a myriad of factors including insulin insufficiency and impaired glucose utilization. Its complications span a broad spectrum, encompassing vascular diseases and neurological impairments. While some risk factors are beyond control, such as age and genetics, others like diet and exercise offer avenues for risk mitigation. This review delineates the distinct pathogenic processes of the two primary forms of DM, type 1 and type 2, emphasizing their differential etiologies and epidemiological trends. Biomarkers play a pivotal role in the diagnosis and management of DM, offering insights into disease progression, beta-cell function, and therapeutic responses. Traditional biomarkers, alongside predictive markers like autoantibodies, facilitate early detection and intervention strategies. Moreover, advancements in high-throughput "-omics" technologies have unraveled the molecular intricacies underlying disease progression, heralding the discovery of potential serum protein biomarkers in type 1 DM and unveiling promising candidates such as unmethylated insulin DNA and dysregulated microRNAs. In type 2 DM, traditional biomarkers like fructosamine, glycated albumin, and 1,5-anhydroglucitol offer valuable tools for glycemic control assessment, with emerging biomarkers like zinc-alpha-2-glycoprotein holding promise for diabetic nephropathy detection. Despite challenges, ongoing research endeavors hold promise for refining these biomarkers and enhancing diabetes management strategies, thus improving patient outcomes.

1 September 2025 in International Journal of Drug Discovery and Pharmacology
Verified
Journal Article
Open access
PDF file
APAnil Kumar Prajapati
Anil Kumar Prajapati
GSGaurang Shah
Gaurang Shah
Cardiovascular diseases (CVDs) remain a leading cause of death globally, particularly in low- and middle-income regions, with heart failure (HF), arrhythmia, hypertension, myocardial infarction (MI), and myocardial fibrosis among the most prominent conditions. Current therapeutic strategies focus on chemical treatments targeting neurohumoral systems like the renin-angiotensin-aldosterone system (RAAS) and employing combination therapies such as β‍-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and newer agents like Sodium-glucose cotransporter-2 (SGLT-2) inhibitors. However, alkaloids—naturally occurring compounds with nitrogen atoms—are emerging as promising agents in CVD treatment. Alkaloids are found in various natural sources and exhibit cardioprotective, anti-inflammatory, and anti-arrhythmic properties. This review highlights the mechanisms of action of several key alkaloids in heart failure, arrhythmia, hypertension, myocardial infarction, and fibrosis.

8 September 2025 in Egyptian Liver Journal
Verified
Journal Article
Open access
PDF file
NBNarendra S. Bhatt
Narendra S. Bhatt
APAnil Kumar Prajapati
Anil Kumar Prajapati
GSGaurang Shah
Gaurang Shah
Chronic liver disease (CLD) remains a major global health concern, necessitating robust experimental models for advancing research and therapy development. This review highlights the crucial role of both animal and in vitro models in elucidating disease mechanisms and identifying therapeutic targets. Key findings highlight that while chemically and drug-induced animal models effectively replicate aspects of human liver pathology, their translational relevance varies depending on the disease context. In vitro models, particularly 3D cultures and microfluidic systems, are rapidly evolving to mimic the liver’s complex microenvironment better, improving drug screening and mechanistic studies. The review highlights that an integrative approach—combining suitable animal models and advanced in vitro models—offers the greatest potential for understanding CLD progression and accelerating the development of effective, targeted treatments. This comprehensive review covers animal and in vitro models of chronic liver diseases.

15 June 2024 in IP International Journal of Comprehensive and Advanced Pharmacology
Verified
Journal Article
Open access
PDF file
APAnil Kumar Prajapati
Anil Kumar Prajapati
AGAkshmita Gairola
Akshmita Gairola
MMMustakim Mansuri
Mustakim Mansuri
Insulin resistance and neurodegenerative diseases - IJCAAP- Print ISSN No: - 2581-5555 Online ISSN No:- 2456-9542 Article DOI No:- 10.18231/j.ijcaap.2024.013, IP International Journal of Comprehensive and Advanced Pharmacology-IP Int J Compr Adv Pharmacol